COX-2 Review Highlights “Conundrum” Of FDA Drug Safety Regulation
Executive Summary
FDA's summary of the COX-2 inhibitor safety review underscores the "conundrum" posed by drug safety regulation
You may also be interested in...
Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options
Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states
Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options
Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states
Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor